Making A Mark In Materials Science

An Interview With In Vivo Rising Leader Jun Chen

As the leader of UCLA’s Wearable Bioelectronics Research Group, Jun Chen, assistant professor and one of In Vivo’s 2021 Rising Leaders, is deploying sensors, energy-hosting tiles, smart textiles and other technologies to tackle big problems, from health care to sustainable energy.  

smart clothing

Back To Rising Leaders Gallery

The uses and potential applications of digital monitoring technologies, in service of better human health, are multiplying. Clinical trial investigators...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics

 
• By 

By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By 

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By 

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

More from In Vivo

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

Deals In Depth: October 2025

 
• By 

Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.

Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines

 
• By 

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.